AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Neomorph will receive an undisclosed upfront ... based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in a deal worth more than $1 billion. Back in December, AbbVie ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

MGDs are not a new concept – established blood cancer drugs Bristol-Myers ... San Diego, California-based Neomorph was set up in 2020 by investment group Deerfield Management, coming out of ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we see new data on a next-generation obesity candidate from ...

Biogen and Neomorph have entered a research partnership aimed at discovering and developing molecular glue degraders for the ...

Neomorph Inc. has signed another billion-dollar deal to develop molecular glue degraders, this time with Abbvie Inc. It’s the third agreement in the past year the five-year-old company has signed with ...

AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and ...

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is ...

(RTTNews) - AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology ...